Drugs / Icaritin
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02496949 | Nov 2011 → May 2013 | cancer | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01278810 | Nov 2010 → Nov 2011 | breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06896396 | Apr 2025 → Jun 2027 expected | hepatocellular carcinoma | Zhiyong Huang | Not yet recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07337460 | Nov 2025 → Nov 2027 expected | hepatocellular carcinoma | Northern Jiangsu People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06825546 | Apr 2025 → Apr 2027 expected | pancreatic ductal adenocarcinoma | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06285149 | Mar → Dec 2024 | hepatocellular carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT07328828 | Mar 2024 → Mar 2025 overdue | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05903456 | Jul 2023 → May 2025 | hepatocellular carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01972672 | Oct 2013 → Aug 2015 | hepatocellular carcinoma | Beijing Shenogen Biomedical Co., Ltd | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05594927 | Dec 2022 → Aug 2025 overdue | hepatocellular carcinoma | Beijing Shenogen Biomedical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT03236649 | Sep 2017 → Feb 2022 | hepatocellular carcinoma | Beijing Shenogen Biomedical Co., Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT03236636 | Sep 2017 → Dec 2022 | hepatocellular carcinoma | Beijing Shenogen Biomedical Co., Ltd | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06269445 | Jan 2024 → Feb 2025 | colorectal cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06893887 | May 2025 → Mar 2027 expected | hepatocellular carcinoma | Nanjing Tianyinshan Hospital | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Icaritin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03236636 ↗ |
| Known as | Icaritin soft capsule | “Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials.” NCT05903456 ↗ |
| Known as | SGN-162 | ChEMBL registry synonym — accepted as the source's own label CHEMBL498485 ↗ |
| Action | Inhibit | “By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role.” NCT05903456 ↗ |
| Modality | Small molecule | “Icaritin is a newly discovered small molecular compound” NCT01278810 ↗ |
| Route | Oral | “ascending-multiple oral dose” NCT01278810 ↗ |
| Target | TNF | “Icaritin can downregulate the expression of TNF-α, IL-6, PD-L1” NCT06285149 ↗ |